MY165499A - Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) - Google Patents
Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)Info
- Publication number
- MY165499A MY165499A MYPI2013701814A MYPI2013701814A MY165499A MY 165499 A MY165499 A MY 165499A MY PI2013701814 A MYPI2013701814 A MY PI2013701814A MY PI2013701814 A MYPI2013701814 A MY PI2013701814A MY 165499 A MY165499 A MY 165499A
- Authority
- MY
- Malaysia
- Prior art keywords
- tfpi
- monoclonal antibodies
- tissue factor
- pathway inhibitor
- factor pathway
- Prior art date
Links
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 title abstract 2
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 title abstract 2
- 101150070659 tfpI gene Proteins 0.000 title 1
- 101000653189 Homo sapiens Tissue factor pathway inhibitor Proteins 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471101P | 2011-04-01 | 2011-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY165499A true MY165499A (en) | 2018-03-27 |
Family
ID=46932389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2013701814A MY165499A (en) | 2011-04-01 | 2012-03-30 | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| MYPI2017001205A MY190951A (en) | 2011-04-01 | 2012-03-30 | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017001205A MY190951A (en) | 2011-04-01 | 2012-03-30 | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
Country Status (37)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104984319B (zh) | 2008-12-19 | 2025-05-09 | 武田药品工业株式会社 | Tfpi抑制剂和使用方法 |
| US8450275B2 (en) | 2010-03-19 | 2013-05-28 | Baxter International Inc. | TFPI inhibitors and methods of use |
| EP3260466A1 (en) | 2008-12-22 | 2017-12-27 | Novo Nordisk A/S | Anti-tfpi antibodies |
| LT3345615T (lt) | 2010-03-01 | 2020-02-10 | Bayer Healthcare Llc | Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi) |
| CN107090046A (zh) * | 2011-04-01 | 2017-08-25 | 拜尔健康护理有限责任公司 | 针对组织因子途径抑制物(tfpi)的单克隆抗体 |
| JP2015514070A (ja) * | 2012-03-21 | 2015-05-18 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | Ｔｆｐｉ阻害剤および使用方法 |
| WO2013148248A1 (en) * | 2012-03-30 | 2013-10-03 | Bayer Healthcare Llc | Protease-regulated antibodies |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| EP2970499B1 (en) | 2013-03-15 | 2022-08-10 | Novo Nordisk A/S | Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor |
| EP2970497B1 (en) | 2013-03-15 | 2017-10-25 | Bayer HealthCare LLC | Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics |
| JP6584397B2 (ja) * | 2013-07-19 | 2019-10-02 | ノヴォ ノルディスク アー／エス | 凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体 |
| JP6783754B2 (ja) * | 2014-09-17 | 2020-11-11 | ノヴォ ノルディスク アー／エス | 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体 |
| CA2977621C (en) * | 2015-02-25 | 2021-11-23 | Mogam Institute For Biomedical Research | Antibody binding to tfpi and composition comprising the same |
| CN107922506B (zh) * | 2015-08-19 | 2021-11-09 | 辉瑞公司 | 组织因子途径抑制剂抗体及其用途 |
| WO2020021890A1 (ja) * | 2018-07-25 | 2020-01-30 | ソニー株式会社 | 血液凝固系解析装置 |
| CN112442127A (zh) * | 2019-08-29 | 2021-03-05 | 苏州康宁杰瑞生物科技有限公司 | 针对tfpi的单克隆抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06153985A (ja) * | 1992-11-16 | 1994-06-03 | Teijin Ltd | モノクローナル抗体 |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| EP3260466A1 (en) * | 2008-12-22 | 2017-12-27 | Novo Nordisk A/S | Anti-tfpi antibodies |
| LT3345615T (lt) * | 2010-03-01 | 2020-02-10 | Bayer Healthcare Llc | Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi) |
| CN107090046A (zh) * | 2011-04-01 | 2017-08-25 | 拜尔健康护理有限责任公司 | 针对组织因子途径抑制物(tfpi)的单克隆抗体 |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
-
2012
- 2012-03-30 CN CN201710275470.2A patent/CN107090046A/zh active Pending
- 2012-03-30 ES ES12762959T patent/ES2722824T3/es active Active
- 2012-03-30 BR BR112013025376A patent/BR112013025376A2/pt active Search and Examination
- 2012-03-30 DK DK12762959.0T patent/DK2694544T3/en active
- 2012-03-30 RS RS20190338A patent/RS58633B1/sr unknown
- 2012-03-30 HU HUE12762959A patent/HUE042706T2/hu unknown
- 2012-03-30 JP JP2014502846A patent/JP6170903B2/ja not_active Expired - Fee Related
- 2012-03-30 EA EA201301107A patent/EA034214B1/ru not_active IP Right Cessation
- 2012-03-30 UA UAA201312686A patent/UA113623C2/uk unknown
- 2012-03-30 CA CA3068997A patent/CA3068997A1/en not_active Abandoned
- 2012-03-30 MY MYPI2013701814A patent/MY165499A/en unknown
- 2012-03-30 HR HRP20190467TT patent/HRP20190467T1/hr unknown
- 2012-03-30 SI SI201231558T patent/SI2694544T1/sl unknown
- 2012-03-30 CA CA2831907A patent/CA2831907C/en not_active Expired - Fee Related
- 2012-03-30 PL PL12762959T patent/PL2694544T3/pl unknown
- 2012-03-30 CN CN201280026938.XA patent/CN103797030B/zh not_active Expired - Fee Related
- 2012-03-30 SG SG10201602606UA patent/SG10201602606UA/en unknown
- 2012-03-30 EA EA201991704A patent/EA201991704A3/ru unknown
- 2012-03-30 KR KR1020137028821A patent/KR101995302B1/ko not_active Expired - Fee Related
- 2012-03-30 AU AU2012236296A patent/AU2012236296A1/en not_active Abandoned
- 2012-03-30 WO PCT/US2012/031538 patent/WO2012135671A2/en not_active Ceased
- 2012-03-30 PE PE2013002137A patent/PE20141149A1/es active IP Right Grant
- 2012-03-30 LT LTEP12762959.0T patent/LT2694544T/lt unknown
- 2012-03-30 MY MYPI2017001205A patent/MY190951A/en unknown
- 2012-03-30 EP EP12762959.0A patent/EP2694544B1/en active Active
- 2012-03-30 SG SG2013071477A patent/SG193594A1/en unknown
- 2012-03-30 TR TR2019/05101T patent/TR201905101T4/tr unknown
- 2012-03-30 US US14/009,334 patent/US20140294832A1/en not_active Abandoned
- 2012-03-30 PT PT12762959T patent/PT2694544T/pt unknown
- 2012-03-30 KR KR1020197018445A patent/KR20190079698A/ko not_active Ceased
- 2012-03-30 MX MX2013011218A patent/MX2013011218A/es unknown
-
2013
- 2013-09-27 GT GT201300229A patent/GT201300229A/es unknown
- 2013-09-30 CU CU2013000128A patent/CU20130128A7/es unknown
- 2013-09-30 CR CR20130499A patent/CR20130499A/es unknown
- 2013-09-30 PH PH12013502039A patent/PH12013502039A1/en unknown
- 2013-09-30 CL CL2013002811A patent/CL2013002811A1/es unknown
- 2013-09-30 DO DO2013000218A patent/DOP2013000218A/es unknown
- 2013-09-30 IL IL228633A patent/IL228633B/en active IP Right Grant
- 2013-10-01 EC ECSP13012913 patent/ECSP13012913A/es unknown
- 2013-10-01 CO CO13233113A patent/CO6890074A2/es unknown
- 2013-10-31 ZA ZA2013/08169A patent/ZA201308169B/en unknown
-
2016
- 2016-07-27 US US15/221,104 patent/US20170107298A1/en not_active Abandoned
-
2017
- 2017-02-17 JP JP2017027825A patent/JP6363747B2/ja not_active Expired - Fee Related
- 2017-05-10 AU AU2017203105A patent/AU2017203105A1/en not_active Abandoned
-
2018
- 2018-01-22 US US15/877,349 patent/US20180194857A1/en not_active Abandoned
- 2018-01-25 IL IL257145A patent/IL257145A/en unknown
- 2018-02-22 HK HK18102557.1A patent/HK1243426A1/zh unknown
- 2018-06-28 JP JP2018122610A patent/JP2018172411A/ja active Pending
- 2018-12-27 US US16/234,239 patent/US20190194353A1/en not_active Abandoned
-
2019
- 2019-02-28 PH PH12019500440A patent/PH12019500440A1/en unknown
- 2019-02-28 PH PH12019500439A patent/PH12019500439A1/en unknown
- 2019-02-28 PH PH12019500441A patent/PH12019500441A1/en unknown
- 2019-03-15 AU AU2019201814A patent/AU2019201814A1/en not_active Abandoned
- 2019-03-22 CY CY20191100343T patent/CY1121538T1/el unknown
-
2020
- 2020-05-14 IL IL274686A patent/IL274686B/en unknown
- 2020-10-20 JP JP2020176145A patent/JP2021019619A/ja not_active Withdrawn
-
2021
- 2021-03-24 US US17/211,631 patent/US20220041752A1/en not_active Abandoned
- 2021-06-09 IL IL283829A patent/IL283829A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500439A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| PH12018500641A1 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| PH12017502286A1 (en) | Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi) | |
| TN2012000144A1 (en) | Dll4-binding molecules | |
| EA201492101A1 (ru) | Антитела против fcrn | |
| EP2668212A2 (en) | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| MX357965B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
| EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
| EA201291034A1 (ru) | АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ | |
| EA201491011A1 (ru) | Способы лечения с помощью ингибитора гамма-интерферона | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| EA202090031A3 (ru) | Человеческие антитела против gfr3 и способы их применения | |
| GB201109238D0 (en) | Antibodies | |
| WO2013013025A3 (en) | Anti-cxcr4 antibodies and methods of use | |
| MX354270B (es) | Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. . | |
| MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
| MX2013009529A (es) | Tratamiento de enfermedad de crohn con fistulas. | |
| HK1190415A (en) | Humanised anti-cd52 antibodies |